US 11,173,196 · Application 16/111,120 · Granted Nov 16, 2021
US 11,173,196
Vectors for expression of prostate-associated antigens
Estimated expiration
—
- Maintenance fee lapse detected.
- Patent may have expired due to maintenance fees: Patent Expired Due to NonPayment of Maintenance Fees Under 37 CFR 1.362
Earliest effective filing
Aug 23, 2018
+ 20 years
—
PTA +0d
—
No TD
—
Final
—
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- August 23, 2018
- Earliest effective filing
- August 23, 2018
- Issue date
- November 16, 2021
- PTA
- 0 days
- Base expiry (before PTA)
- —
August 23, 2018 + 20 years = —
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 16/111,120 · US 11,173,196
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 11,173,196: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US11173196Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.